Skip to main
PCVX
PCVX logo

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. is positioned favorably within the biopharmaceutical sector, particularly due to the impressive immunogenic response demonstrated by its product candidates VAX-24 and VAX-31, which have outperformed existing competitors such as Prevnar 20 in adult studies. The company shows a strong potential for leadership in the next-generation pneumococcal vaccine market, backed by high expectations for robust seroresponse rates in infants and substantial projected global revenue opportunities of $7-10 billion. Despite the potential for risks in U.S. vaccine policies, Vaxcyte’s advancing clinical data presents a compelling case for long-term investment, suggesting a significant upside potential for its shares over the next few years.

Bears say

The financial outlook for Vaxcyte Inc appears negative due to several critical risks that could hinder its growth and profitability. The company faces potential delays in research and development, regulatory approvals, and commercial uptake, all of which could significantly impact investor confidence and stock performance. Furthermore, if Vaxcyte's vaccine candidates fail to demonstrate safety and efficacy in clinical trials or if competitors advance faster, the company's ability to capture market share and generate projected revenues could be severely limited, leading to a pessimistic market sentiment.

Vaxcyte (PCVX) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.